AgomAb Therapeutics NV (AGMB) vs Scribe Therapeutics (SCTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 11, 2026.
Summary
AgomAb Therapeutics NV is the larger company by market cap ($447.2 million vs $400.8 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AGMB | SCTX |
|---|---|---|
| Share price | $9.08 | $21.17 |
| Market cap | $447.17M | $400.78M |
| 1-day change | -1.52% | +10.09% |
| EPS (TTM) | $-2.08 | $-3.84 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $17.82 | $39.60 |
| 52-week low | $7.97 | $13.50 |
| Distance from 52-week high | -49.05% | -46.54% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +314.87% | +169.25% |
| Average volume | 140.06K | 358.12K |
| Shares outstanding | 49.25M | 18.93M |
| Employees | 62 | 82 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About AgomAb Therapeutics NV
AGMB stock →AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases in the United States. The company's product pipeline includes Ontunisertib (AGMB-129), an oral gastrointestinal-restricted small molecule inhibitor of ALK5 or TGFßR1 for the treatment of Fibrostenosing Crohn's disease, which is in Phase 2a clinical trials; and AGMB-447, an inhaled small molecule inhibitor of ALK5 or TGFßR1 for the treatment of idiopathic pulmonary fibrosis that is in Phase 1 clinical trials.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 62 employees
About Scribe Therapeutics
SCTX stock →Scribe Therapeutics Inc. operates as a clinical-stage biotechnology company, focuses on research and developing genetic medicines using CRISPR-based tools to address the root cause of diseases, with a primary focus on cardiometabolic conditions in the United States.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 82 employees
AGMB vs SCTX FAQ
Which is bigger, AgomAb Therapeutics NV or Scribe Therapeutics?
AgomAb Therapeutics NV (AGMB) is larger, with a market capitalization of $447.17M compared with $400.78M for Scribe Therapeutics (SCTX).
Are AgomAb Therapeutics NV and Scribe Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.